创伤后发作,抗发作药物和创伤后记忆丧失的持续时间之间的关联:回顾性队列分析
Sergiu Albu1, Oyku Arslantas2, Hatice Kumru1
1Neurology Department, Institut Guttmann, Institut Universitari de Neurorehabilitació Adscrit a la UAB, Barcelona, Spain; Universitat Autónoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Barcelona, Spain; Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain.
Archives of physical medicine and rehabilitation
|October 2, 2025
概括
抗发作药物 (ASM) 的使用与创伤后脑损伤 (TBI) 患者的创伤后记忆丧失 (PTA) 持续时间更长有关. 仔细评估ASM的使用对于优化PTA的TBI患者的结果至关重要.
科学领域:
- 神经科学是一个神经科学.
- 创伤学 创伤学 创伤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 创伤性脑损伤 (TBI) 可以导致持续的创伤后记忆丧失 (PTA).
- 抗发作药物 (ASM) 在影响PTA持续时间方面的作用尚未完全理解.
研究的目的:
- 调查创伤后发作 (PTS),ASM使用和TBI后PTA持续时间之间的关联.
主要方法:
- 在TBI后接受神经康复治疗后,352名PTA患者的回顾性研究.
- 分析包括患者人口统计,格拉斯哥昏迷量表,加尔维斯顿定向和失忆测试 (GOAT) 评分,PTS存在和ASM使用情况.
- 考克斯的比例危险模型被用来确定与PTA持续时间相关的因素.
主要成果:
- 与接受ASM治疗PTS,预防或其他疾病的组相比,无ASM组的PTA持续时间中位数最短 (59.1天).
- 年龄较大,入院GOAT得分较低和PTS治疗与PTA持续时间较长有显著联系.
- 用ASM治疗PTS或行为/疼痛指示的患者的PTA持续时间比不使用ASM的患者更长.
结论:
- ASM使用,年龄较大和入院GOAT得分较低与TBI患者的PTA持续时间延长有关.
- 在TBI患者中,即使没有发作,ASM使用率很高,强调需要明智的处方来改善结果.
相关概念视频
Amnesia
456
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
456
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Traumatic Memory
551
Emotionally traumatic events often lead to memories that are exceptionally vivid and enduring, sometimes persisting with remarkable clarity throughout an individual's life. A classic example of this phenomenon is a person who survives a car accident. Even years later, they may recall every detail of the event with startling accuracy — the screeching of the tires, the jarring impact, and the acrid smell of burning rubber. Such vividness contrasts sharply with how an individual...
551
Seizures: Classification
1.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
827
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
827


